| Patient | Dwight D. Eisenhower |
|---|---|
| Date of birth | 1960-10-14 |
| Identifiers | MRN HR-ET015-SYN; SSN (made up) 000-15-2673 |
| Document date | 2026-01-26 |
| Author | Russell Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week blood pressure and kidney check after increasing lisinopril. [S]
Mr. Eisenhower returns two weeks after lisinopril was increased to 10 mg and ezetimibe was added. He has had no dizziness, cough, or muscle aches. His home blood pressure has been 124 to 130 over 76 to 80. He is still working half days and walks 40 minutes most days without chest pain or breathlessness. He has not needed nitroglycerin. His echocardiogram and cardiology consultation were done this morning, and he was told he can return to full-time work; he plans to start next week. [S]
| Element | Detail |
|---|---|
| Interval change | No symptoms on the higher lisinopril dose or on ezetimibe |
| Home blood pressure | 124 to 130 over 76 to 80 |
| Exercise | Walking 40 minutes most days without angina |
| Nitroglycerin use | None |
| Adherence | Every dose of aspirin, ticagrelor, atorvastatin, ezetimibe, metoprolol, and lisinopril |
| Work | Half days; full-time return planned next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No muscle aches on statin and ezetimibe |
| Neurological | Negative | No dizziness on standing |
| Hematologic | Positive | Easy bruising on the forearms; no other bleeding |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-24 | active | S |
| Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2025-09-24 to 2026-09-28 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-24 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-25 | active | S |
| Lisinopril 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-26 to 2026-01-12 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 2025-09-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-26 | Body height | 178 | cm | S |
| 2026-01-26 | Body weight | 78.6 | kg | S |
| 2026-01-26 | Body mass index (BMI) [Ratio] | 24.8 | kg/m2 | S |
| 2026-01-26 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-01-26 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-01-26 | Heart rate | 60 | /min | S |
| 2026-01-26 | Respiratory rate | 14 | /min | S |
| 2026-01-26 | Body temperature | 36.7 | Cel | S |
| 2026-01-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-26 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-01-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-26 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-01-26 | Left ventricular Ejection fraction | 52 | % | 50-70% | Normal | S |
Vital signs recorded on 2026-01-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, alert, and eager to get back to work |
| Neck | No jugular venous distension; no carotid bruits |
| Heart | Regular rhythm; no murmur or gallop |
| Lungs | Clear |
| Extremities | No edema; right radial access site healed |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Anterior ST-elevation myocardial infarction about four months before intake, treated with a drug-eluting stent to the left anterior descending artery; synthetic modern episode linked to the documented 1955 anterolateral infarction | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1955 infarction remains D in the history. |
| Coronary artery disease, single-vessel, after stenting; no angina | active | confirmed | I25.10 | S — Synthetic diagnosis supporting secondary prevention. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime is used. |
| Former heavy cigarette smoker, quit about seven years before intake | active | confirmed | Z87.891 | S — Synthetic coded history echoing the documented heavy smoking and quitting around 1949. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel (potassium, creatinine, eGFR) | 1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 months | Completed today | Two weeks after lisinopril was increased to 10 mg. Potassium 4.6, creatinine 1.04 mg/dL, eGFR 80; normal |
| Imaging | Echocardiogram for LVEF reassessment about 40 days after the infarction | Once, about 40 days after the infarction, when the hospital LVEF was reduced | Deferred | The hospital ejection fraction was 45 percent, so a repeat was due about 40 days after the infarction, before he established care here; it was not done. Done today at about four months instead: LVEF 52 percent, so no defibrillator evaluation is needed and no harm resulted. Corrective action: discharge plans from outside hospitals are now reconciled at the intake visit |
| Imaging | Transthoracic echocardiogram | Reassess with clinical change | Completed today | LVEF 52 percent, mild apical hypokinesis, no thrombus or aneurysm, normal valves |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing therapy, then every 3 to 12 months | Due | Ezetimibe added two weeks ago; recheck in about two months |
| Examination | Blood pressure, heart rate, weight and BMI, heart and lungs, edema | Every visit | Completed today | Blood pressure 128/78 mmHg, heart rate 60, weight 78.6 kg |
| Medication safety | Antiplatelet, statin, beta-blocker, and ACE inhibitor adherence and tolerance | Every visit | Completed today | Taking all doses; forearm bruising only; no cough, dizziness, or myalgia |
| Referral | Cardiology evaluation | After the infarction, to establish local cardiology care | Completed today | Seen today; cleared for full-time work and long-distance travel |
| Referral | Cardiac rehabilitation | Within 12 months of the infarction; 36 sessions | Completed today | All 36 phase 2 sessions completed; exit test 9 METs. Continues a home maintenance program |
| Survey | Depression screen (PHQ-2) | Every visit | Up to date | Score 1 at intake two weeks ago; repeat at the lipid review |
| Self-management | Tobacco use | Every visit | Completed today | Abstinent; no exposure at work or home |
| Self-management | Physical activity and Mediterranean-style diet | Every visit | Completed today | Walking 40 minutes most days; diet reviewed |
| Examination | Defibrillator evaluation | At least 40 days after the infarction and 90 days after revascularization if LVEF is 35 percent or less | Not indicated | LVEF 52 percent |
Goal progress:
Guideline basis: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026)
Follow-up: Lipid panel and review in about two months. Call for chest pain that does not settle with one nitroglycerin tablet in 5 minutes. Next scheduled visit 2026-03-16: lipid review nine weeks after adding ezetimibe. [S]